Tag: Business

August 11: India’s leading Ayurvedic and Natural Health Care Company, Dabur India Ltd, today announced the Launch of the Dabur Vedic Tea portfolio with the launch of “Dabur Vedic Green Tea Detox Kahwa”, a Green Tea infused with Ayurvedic Herbs and Rock Salt.

“Catering to modern consumer’s healthy lifestyle and as part of our commitment to health & well-being for all, we are delighted to announce the expansion of the Dabur Vedic Tea product range with the launch of “Dabur Vedic Green Tea Detox Kahwa”. Unlike regular green tea, Dabur Vedic Green Tea Detox Kahwa is infused with 8 real Ayurvedic Herbs and Rock Salt. It is a Gluten Free product which helps in Detoxification, Weight Loss, Boosting Metabolism and improving Digestion and leaves a lovely Salty and Spicy Zing on the tongue. We are confident that our new product will help consumers to have health-conscious choices in their beverage space”. Mr. Smerth Khanna, Head of Ecommerce and Modern Trade, Dabur India Ltd, said.

Priced at Rs.275 for 25 Tea Bags, Dabur Vedic Green Tea Detox Kahwa is launched on the leading e-commerce platform Amazon India. There is an introductory launch offer of 24% off that consumers can avail of. The product will be rolled out in other sales channels soon.

“We are delighted to launch ‘Dabur Vedic Green Tea Detox Kahwa’ for our customers on Amazon.in. Dabur is a household name and brand of choice when it comes to a healthy and natural range of products and as well as daily essentials. In the recent past, we have observed an increase in the demand for products with healthy living options on Amazon.in, green tea being one of them. With this partnership, we take a step further in our effort to offer customers a vast and diverse selection, unmatched value, fast and reliable delivery and a great shopping experience on Amazon.in,” said Amazon India director – Core Consumables Nishant Raman.

Mr. Prashant Agarwal, Marketing Head- Health Supplements, Dabur India Ltd, said, “With the rising health awareness in India, customers prefer products that help improve their healthy lifestyle. The new-age consumers are increasingly shifting away from regular tea to health-based options. With over 138 Years of Ayurveda Legacy, Dabur brings you our Ayurvedic expertise into your daily cup of tea with Dabur Vedic Green Tea Detox Kahwa. Made with 8 whole herbs like Black Pepper, Ginger, Tulsi, Hing, Clove, Cardamom, Cinnamon and Nutmeg, it brings you the goodness of health in every cup”.

About Dabur India Ltd: Dabur India Ltd is one of India’s leading FMCG Companies. Building on a legacy of quality and experience for 138 years, Dabur is today India’s most trusted name and the world’s largest Ayurvedic and Natural Health Care Company. Dabur India’s FMCG portfolio includes nine Power Brands: Dabur Chyawanprash, Dabur Honey, Dabur Honitus, Dabur Lal Tail and Dabur Pudin Hara in the Healthcare category; Dabur Amla, Vatika and Dabur Red Paste in the Personal care space; and Réal in the Food & Beverages category.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Dabur launches Dabur Vedic Green Tea Detox Kahwa appeared first on Republic News Today.

August 11: Ajmal Perfumes, a globally known, homegrown brand with a rich heritage and seven decades of craftsmanship in the intricate art of perfumery, announces its plans to strengthen its foothold in India by extending its retail presence via an extensive franchise partner network. The brand will initiate the expansion with potential partners by participating in the Franchise India’s Expo at Pragati Maidan on 20th & 21st August 2022.

Ajmal stands strong as a global fragrance leader with a vast portfolio of around 1000 of the finest and most captivating fragrances available across 45 countries. In addition to its owned 34 Kiosks and Small Format Stores, Ajmal Perfumes has already embarked on this expansion program with two of its latest Franchise stores active in Jalandhar and Ludhiana. As part of its retail strategy to make the products accessible at an arm’s length of desire, the brand plans to expand to nearly 34,000Point Of Sale by 2025. Today, Ajmal Perfumes reaches consumer segments across India with 4,000+ Point Of Sale by leveraging a unique distribution set up across General Trade and Modern Trade and to more than 10000 pin codes by E-commerce.

At each of the Franchise stores, consumers will have access to not just world-class fragrances but also collections that have now become household names in recent times due to their commercial acceptance. This would mean the entire product portfolio from the House of Ajmal Perfumes, which includes the Ajmal Perfumes X House of Anita Dongre collection, The Make in India Range, and mostnotablyAmir One, which is a globally renowned masterpiece.

“With the growing popularity of Ajmal Perfumes in India, we are extending our fragrance partnership to bring the brand within an arm’s length of desire, to revolutionize the fragrance sector in India by leveraging our experience, heritage, and legacy with our ability to deliver a high-quality product at the right price. We have had consumers asking repetitively to have a full range of Ajmal products, which is only possible when you have a store that carries the entire product portfolio. The Ajmal experience matters to consumers, and it is only possible to deliver it across India when we penetrate deeper into India’s different geographical markets. In this journey, we feel that trying to do it all alone will have limited coverage. This is where able partners who want to carry the legacy of Ajmal Perfumes with mutual benefits will help us expand the Ajmal patronage.”

– says Saurav Bhattacharya, President, Ajmal & Sons – NHA Division, India. 

For more Franchise Enquiries, please contact Bhagwan Sable on +91 9620309997 / franchise.enquiry@nha-world.com.

Or

visit our Franchise India exhibition Booth Nos. VB23 in Hall 2.

About Ajmal Perfumes:

Founded by the Late Haji Ajmal Ali in the early 1950s – in Assam, India – the journey of Ajmal Perfumes is that of the story of ‘A Farmer to A Perfumer’. Ajmal Perfumes has grown from a modest trading house into a multi-million-dollar corporate entity thanks to Late Haji Ajmal Ali’s vision and unstinting dedication to the craft of perfumery. Ajmal’s business – headquartered out of Dubai, United Arab Emirates – is steered by the passion of Ajmal’s second and third generations, each playing a pivotal role in the brand’s development and growth. In its entirety, Ajmal Perfumes is a brand with a rich heritage acquired through almost seven decades of experience and know-how in the intricate art of perfumery.

The brand has a strong retail presence with over 240+ exclusive retail outlets across the GCC and the world.  Ajmal also has a presence on the international front, currently exporting to 45+ countries across the globe and with an exclusive presence through select 30 global Duty-Free locations and International Airlines. In India, Ajmal Perfumes is available at 4,000+ Points of Sale across a mix of channels which comprises Modern Trade, E-commerce, General Trade, Multi Brand Outlets and Owned Retail.

For more information, please visit:

Website:  https://in.ajmalperfume.com/

Instagram: https://instagram.com/ajmalperfumesin?utm_medium=copy_link

Facebook: https://m.facebook.com/AjmalPerfumesIN/

Youtube: https://www.youtube.com/channel/UC2nO1cSFUI61aKR4LVQpUHw

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Ajmal Perfumes aims rapid expansion with 65 Franchise Stores by 2024 appeared first on Republic News Today.

August 10: In a major development at the board meeting today, India’s leading home-grown footwear brand Liberty Shoes announced their unaudited results for Q1 ending 30^th June 2022.

Commenting on the development of the footwear sector, Mr. Anupam Bansal, Director RETAIL and other board of directors at the meeting said, “With the focus of Government on the manufacturing sector, the future potential of the footwear industry is promising, particularly for established and organized brands. Rising disposable income is allowing individuals to move up the value chain, demanding products for different occasions, leading to new product segments in footwear.

Also, in recent times, Liberty has quickly spotted this emerging segment and has adapted strategies and earmarked significant investments to tap this market. A perfect interface has been enabled with the emergence of online marketplaces and support infrastructure for logistics and billing. Omni channel presence is the new buzzword, and Liberty is rushing to reap this trend. All this translates into a bonanza of greater availability, convenience and price optimization for consumers, helping them make informed shopping decisions.

Below is the comprehensive highlight of the Quarter results.

(Rs. in Lakh except EPS)      

*EBITDA has been mentioned ignoring the implication of accounting treatment of Operating Lease of the Company in accordance with newly implemented Industry AS-116 w.e.f 1^st April 2019. Some of the Key points are –

–  The Company has recorded Revenue from Operations during Q1 2022-23 with an increase of 65% Y-o-Y at Rs. 16,122.10 Lakh as compared to Rs 9,764.49 Lakh in Q1 2021-22. The base quarter for comparing the growth is the affected quarter due to COVID-19, but the Company has witnessed huge demand for school and formal and sports shoes during the quarter under consideration. The Company has observed that overall consumer sentiments have improved considerably, and due to this, the Company has achieved better realization of per pair sales.

–          EBITDA has improved at Rs. 1321.54 Lakh during Q1 2022-23 compared to Rs. 343.21 Lakh during Q1 2021-22. The EBITDA margins have shown sharp improvements during this quarter at 8.19% as against 3.51% during the corresponding quarter of last year because of a better sales mix with higher margin and also effective utilization of resources and controlled input costs other expenses.

–          PBT of the Company has been recorded at Rs. 755.47 Lakh during Q1 2022-23 as against a Loss of Rs. 306.48 Lakh during the corresponding quarter of Q1 2021-22 because of improved cash flows, thereby reduction of bank borrowings resulting in reduced interest cost during the period. The Company has witnessed an improved collection of payments and reduced its dependence on bank borrowings. During the period ended 30^th June 2022, the Company has working capital loan utilization to the extent of Rs. 43 Cr only as against the sanctioned limit of Rs. 115 Cr.

–          PAT of the Company has been recorded at Rs. 547.34 Lakh during this quarter compared to Loss of Rs. 306.48 Lakh during the corresponding quarter of last year. For the period under consideration, the Company has created the provision for Income Tax for ₹ 208 Lakhs.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post LIBERTY SHOES announced its Q1 ended 30th June, 2022 Unaudited Financial Results appeared first on Republic News Today.

Mr. Rajiv Gandhi, CEO & MD, Hester Biosciences Ltd

August 10: One of India’s leading poultry and animal vaccine manufacturing companies, Hester Biosciences Limited, has reported a consolidated net profit of Rs. 3.56 crore and Revenue from Operations of Rs. 50.70 crores for the Q1FY23. Individually, the gross margins of the vaccines and the health products have been in line with the corresponding quarter; however, the overall margins have reduced due to the increase in the proportion of health products sales which have lower gross margins compared to vaccines. Health Products sales constituted 34% of the total sales in Q1 FY23, versus 20% in Q1 FY22.

Hester Tanzania recently received regulatory approvals for four products, with two additional products under approval. Hester Tanzania has just started commercial operations, and Revenues are expected to start in Q2. Hester Nepal has registered a 16% growth in domestic revenues; however, there were no tender sales in the current quarter due to delays in tendering by FAO and other multilateral institutions.

Going further

The company is confident of arresting the de growth in Q2 as well as hopes to improve the profitability as follows:

On the vaccine side:

1. The recent outbreak of Lumpy Skin Disease (LSD) in certain parts of the country since July 2022 is expected to result in additional sales in Q2 FY23.
2. The Company was a successful bidder in a government tender for PPR vaccine for sheep & goats, the supplies for which will likely start from September 2022.

On the Health Product side:

It is our endeavour to improve the profitability. Over the next couple of quarters, Hester will focus on growing sales on the back of improving the sales productivity of the marketing team as well as launching new products and entering new territories.

Petcare division

The Company launched a new division for Petcare during Q1 with ten products. Activities related to market development, field force establishment and product pipeline are ongoing. Petcare Division will emerge as a steady long-term growth driver, given the increasing adoption of pets in the country.

Status on Hester’s initiatives in the Covid-19 vaccine

• The Company, in consortium with Gujarat Biotechnology Research Centre (GBRC), Government of Gujarat (GoG), has entered into a term sheet agreement with Bharat Biotech India Limited to manufacture the Drug Substance for Covaxinunder the Mission Covid Suraksha Scheme of the Government of India.
• The project is to manufacture a Drug Substance equivalent to up to 7 million doses per month.
• The construction of the BSL-3 facility is nearing mechanical completion. Planning and preparation for commissioning are ongoing. The facility is expected to be ready for commercial operation in Q3FY23.
• This facility is a multi-purpose facility to handle other micro-organisms beyond Covid-19.

Other developments

1. The Company is strengthening its new product vaccine pipeline by developing new vaccines like Classical Swine Fever (CSF), Sheep Pox and an improved version of Brucella vaccines.
2. The bulk antigen production capacity expansion project is completed, and trial runs are ongoing. Expansion of Fill-Finish line capacity is expected to be completed by Q4FY23. These two expansions will double the production capacity of vaccines.
3. The recent notification by the Government of India to allow the manufacture and sale of Avian Influenza Inactivated vaccine, the H9N2 strain, will contribute to our sales from Q3.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Hester Biosciences Ltd reports Net Profit of Rs. 3.56 crore and Revenues from Operations of Rs. 50.7 crore in Q1FY23 appeared first on Republic News Today.

Rajkot, 10 August 2022: Radhika Jeweltech Ltd. (RJL) (BSE: 540125, NSE:RADHIKAJWE), a renowned retail jewelry Company dealing in high-end Legacy jewelry including fine gold jewelry and diamond-studded jewelry operating through a retail store in Rajkot, Gujarat has announced results for the quarter ended 30June, 2022.

Standalone Financial Highlights

For the quarter ended 30 June 2022 the company reported total income of Rs. 61.63 Cr as compared to Rs. 53.1486 crores during the period ended March 31, 2022.For the corresponding period, the net profit stood at 10.21 Cr (Q1FY23) as against Rs. 4.44 Cr (Q4FY22).

The company recorded impressive revenue growth of 163% YoY, which grew from Rs. 23.44 Cr (Q1FY22) to Rs.61.63 (Q1FY23). PAT rose 270% YoY, growing from Rs. 2.76 Cr (Q1FY22) to Rs. 10.21 Cr (Q1FY23). The company reported EPS of Rs.4.33 (Q1FY23) as compared to Rs.1.17 (Q1FY22)

Radhika Jeweltech Ltd. has over 3 decades of goodwill with its customers. With 35 years’ rich experience in gold and jewellery entrepreneurship, the promoters of RJL have in-depth knowledge of the industry as well as the local jewellery market of Rajkot.. Rajkot is the primary socioeconomic urban centre of the Saurashtra region and a major one in the state of Gujarat. Going forward, rapid urbanization, an expanding working-age population, growing economic opportunities, and rising disposable income along with the tradition of buying/investing in gold will drive demand for jewellery.

Mr. Ashok Zinzuwadia, the driving force behind the Company, laid the foundation of Radhika Jewellers back in 1987. Since then, Radhika Jeweltech Limited has experienced rapid growth and expanded from a small shop in soni bazar of Rajkot city in its initial stages to a huge showroom of 2500 sq. ft., which is now situated on palace road of Rajkot city. The success of Radhika Jeweltech Limited can be attributed to their customer-centric philosophy, the quality standards of jewelry, best designs displayed to highly valued customers, outstanding selling skills of employees.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Radhika Jeweltech Ltd Reports Q1FY23 Financial Results; PAT jumps 270% YoY appeared first on Republic News Today.

Mumbai (Maharashtra) [India], August 10: Kingston Technology, a world leader in memory products and technology solutions announced compelling discounts of up to 60% during Amazon’s Great Freedom Festival Sale from 6^th to 10^th Augusts 2022. Now gamers and technology afficionados can grab best-in-class memory products and storage solutions at an amazing price point. Be it for work from home upgrade or for improving your gaming performance if have you covered.

Here is the list of some of the offers that you can’t miss at all:

Kingston FURY Beast DDR4– Provides powerful performance boosts for gaming and rendering with speeds up to 3733MHz and CL15–19 latencies. Those looking for a cost-efficient upgrade for gaming should look nothing beyond Kingston FURY Beast DDR4.  It features Plug n Play automatic overclocking at 2666MHz and are Intel XMP ready and ready for AMD Ryzen

Kingston FURY Beast 8GB 3200MHz DDR4 at 2630/-

Kingston FURY Beast 16GB 3200MHz DDR4 at 4865/-

Kingston FURY Impact DDR4– For notebook/laptop gamers, now they can fully equip their notebook or small form factor machine with Kingston FURY Impact SODIMM. It is perfect for minimizing system lag while gaming. Intel XMP is ready and ready for AMD Ryzen in capacities up to 64GB, Plug N Play Kingston FURY Impact DDR4 auto overclocks to the highest frequency published, up to 3200MHz to support Intel and AMD’s latest CPU technologies. Install the sleek black PCB for a hassle-free boost, no need to tinker with the BIOS, and it still run cool, quiet, and efficiently, thanks to Kingston FURY Impact DDR4’s low 1.2 voltage.

Kingston FURY Impact 8GB 3200MHz DDR4 now at INR 3245/-

Kingston FURY Impact 16GB 3200MHz DDR4 now at INR 6395/-

Kingston ValueRAM – If you are looking to upgrade your PC or Laptop for better functioning, Kingston ValueRAM is a great way to watch your productivity soar: pages will load faster and launching new applications will be easier and faster.

Kingston Value Memory 8GB DDR4 3200Mhz now at INR 2509/-

Kingston NV1 NVMe SSD- Perfect for storage requirements for users looking for entry-level NVMe SSD options.  Kingston NV1 is the ideal entry-level drive for first-time NVMe users with laptops and small form factor PCs for gaming. It is a substantial storage solution with capacities up to 2TB. It features read/write speeds up to 2,100/1,700MB/s, respectively, thus delivering 3X the performance of a SATA-based SSD. Kingston NV1 uses less power, emits less heat and has quicker load times, making it ideal for users who appreciate the responsiveness and ultra-fast data access but have systems with limited space.

Kingston NV1 M.2 NVMe PCIe (SSD) 250GB now at INR 2249/-

Kingston Q500 SSD-. Kingston’s Q500 solid-state drive dramatically improves the responsiveness of your existing system with incredible boot, loading and transfer times compared to mechanical hard drives. Powered by the latest gen controller for reading and write speeds up to 500MB/s and 450MB/s1, this SSD is 10x faster than a traditional hard drive1 for higher performance, ultra-responsive multi-tasking, and an overall faster system. Also, more reliable and durable than a hard drive, Q500 is available in multiple capacities from 120GB–1.92TB2.

Kingston Q500 SATA3 2.5 SSD 240GB now at INR 2599/-

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Kingston Technology offers up to 60% discount for Amazon’s Great Freedom Festival Sale appeared first on Republic News Today.

Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.

India, August 09, 2022: Sandu Pharmaceuticals Ltd., experts in Ayurveda since 123 years and a leading producer of Ayurvedic medicines and products, has launched a new product Sandu Kumarvin. Sandu Kumarvin is a tonic that is useful for the adolescent age group of children aged 2 to 14 years.

Sandu Kumarvin syrup is made with the goodness of Kumari, Draksha, Surwari Haritaki, Arjun, Lavang, Twak and Kiratatikta Ayurvedic herbs that are useful to boost the immunity of children and keep children healthy in all seasons. It also helps absorb various nutritional elements and promotes the child’s overall growth & development.

“Sandu Kumarvin is extremely beneficial in boosting the immunity of children and also helps in preventing recurrent cough and cold. It also helps strengthen the lungs and is an ideal medicine to help prevent respiratory tract infections,” said Dr. Virendra Kumar Kori, Assistant Professor of Kaumarbhritya at the Institute of Post Graduate Teaching & Research in Ayurveda, Jamnagar.

Among other benefits, Sandu Kumarvin is useful in various stomach problems arising due to liver dysfunction such as loss of appetite, ascites, enlarged liver, enlarged spleen, etc. It is also a mild laxative, relieves abdominal gases of distention, and is also helpful in relieving tenacious sputum. Further, it improves the overall liver functions and enhances appetite with improved digestion, leading to positive health in children.

Shashank Sandu – Director, Sandu Pharmaceuticals Ltd

“We, at Sandu, understood the issue of the other products currently present in the market which was not palatable and were disliked by children. We took an initiative for better palatability with a better dosage form to bring out the best medicinal value and to get better results. Sandu Kumarvin has been improved to a flavoured syrup form, which is sweet, palatable and better accepted by children aged between 2 to 14 years.” said Shri. Shashank Sandu, Director, Sandu Pharmaceuticals Ltd.

“The age category between 2 to 14 years, in Sanskrit, is called “Kumar”. The tonic helps fight against diseases and protects the child to ensure he wins in every situation. Hence the name Kumarvin was apt for the product” he added.

“We also offer ‘Sandu Shishuvin’, one of our best sellers which is palatable syrup having similar indication but is useful for newly born infant to 2 years old babies.” he further added.

Experts also stress the need for children to follow a well-balanced diet to avoid problems such as overeating which has an adverse impact on the digestive system. They suggest the consumption of green leafy vegetables, fruits, and herbs to maintain a sound digestive system. Herbs like Guduchi, Draksha, and Ashwagandha, just to name a few, are also great immunity boosters and help children’s health.

For more information, kindly visit the website www.sandu.in

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Sandu Kumarvin, an Ayurvedic digestive and immunity booster for children launched by Sandu Pharmaceuticals Ltd appeared first on Republic News Today.

Mr. Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd

Business Highlights:-

• Total Income in Q1FY23 at Rs. 129.97 crore, up 24.4% from Rs. 104.4 crore in Q4FY22
• Commercial operations of Cephalosporin Plant and Export to EU & Australia to commence in FY23
• Company continuous to remain ‘Net Debt Free’ after multiple expansion & acquisition of Cephalosporin plant
• Robust operational and financial performance during FY12 to FY22 with CAGR Growth 30% in Net profits, 20% in EBITDA and 10% in Revenue.
• CRISIL has upgraded its ratings on the company’s bank facilities to ‘CRISIL A/Stable/CRISIL A1

Ahmedabad, August 9, 2022: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit of Rs. 15.01 crore for the Q1FY23 as against net profit of Rs. 11.10 crore in Q4FY22, growth of 35.2% Q-o-Q. Total income for the quarter ended June 2022 was reported at Rs. 129.97 crore, higher 24.4% Q-o-Q over total income of Rs.104.43 crore in Q4FY22. EBITDA for Q1FY23 was reported at Rs. 23.41 crores as compared to EBITDA of Rs. 19.32 crores in Q4FY22 – growth of 21.14% Q-o-Q. EPS for Q1FY23 was at Rs. 7.49 per share. Exports in Q1FY23 was reported at Rs. 66.08 crore.

Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “FY23 is going to be the growth year for the company. Commercial production from the Mehsana facility for the expansion of Cephalosporin products and exports to EU & Australian markets are expected to commence in the current financial year. Company is growing from strength to strength, delivering robust operational and financial performance, maintaining a healthy growth in revenue, margins and profitability. Company will continue to grow with maintaining its net debt status in future also. We expect the growth momentum to continue while maintaining our ‘Net Debt Free’ status in the coming years.”

During  FY22, company launched 14 products in the domestic market and filled 110 dossiers in the export market. In FY23, company will look to consolidate its position in the lifestyle and chronic segments.

In September 2021, company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products. Company has invested Rs. 30 crore in the cephalosporin plant – including acquisition and subsequent capacity expansion using internal source of funds. The plant is expected to start commercial production in current fiscal and expected to contribute sales of around Rs. 150 crore in the next 3 years. The plant will cater to all the Cephalosporin products i.e. Tablet, Capsule, Dry syrup and Injectable. 

Export business of the company has shown strong growth over the years. It currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. TGA – Australia and EU GMP approvals will strengthen the company’s presence and expand its network to 90 plus countries.

Company has reported a robust financial and operational performance during the last decade (FY12 to FY22) maintaining strong CAGR 30% in Net profits, 20% in EBITDA and 10% in Revenue. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, free cash/liquid investments, no term debt and healthy return ratios.

CRISIL Ratings has upgraded its ratings on the bank facilities of Lincoln Pharmaceuticals Ltd to ‘CRISIL A/Stable/CRISIL A1’ from CRISIL A-/Positive/CRISIL A2+. CRISIL report further states that, “Over the medium term, the group is expected to maintain its growth trajectory and healthy margin. This shall be supported by addition of Cephalosporin which has potential to add around 30% to the topline over next three fiscals. Further, the group’s European market foray shall provide additional fillip to the business profile. Rating agency ICRA too has reaffirmed the company’s long-term and short-term bank facilities to A and A1 respectively. 

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP, TGA – Australia and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others.To complement the company’s strong presence in the acute segment, the company is also building a portfolio in lifestyle and chronic segments especially dermatology, gastro and pain management. Company has filed 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 15.01 crore in Q1FY23 appeared first on Republic News Today.

Jazz Wahan and Shivanshi Chopra at the Launch

August 9: Jazz Wahan, a renowned name in the Make-up industry since decades, launched her Make-up Studio & Palette Luxury Salon in the heart of South Delhi i.e. Greater Kailash 2.

The Make-up studio and salon adorned with luxury interiors and Italian equipment of the brand Maletti has separate floor for the bridal makeup and beauty services. They have looked into finer details of making the experience absolutely amazing … like Music, lighting and scents which plays a huge part in creating an enjoyable atmosphere for their clients.

On the occasion Jazz Wahan said “As a beauty expert my emphasis will be to focus on extraordinary quality, where our customers will leave with an unforgettable experience while using our services. Some of the services that we have included our menu are full range of head to toe pampering, bridals to glam make-up and all kinds of hair and facial treatments “adds Jazz Wahan.

About Jazz Wahan

A renowned Make-up expert and an entrepreneur based out of Delhi, Her expertise lies in the range from Ultra HD bridal looks to Flawless Airbrush natural glam. She has mastered the techniques of highlighting and contouring. She is explicitly known for accentuating the best features of her clients and leaving a soft glow to reflect in all her makeup art.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Jazz Wahan Make-up Studio & Palette Luxury Unisex Salon gets a new address as they launch in the heart of South Delhi appeared first on Republic News Today.

New Delhi (India), August 9: Money Mileage, a new-age money management platform, has received funding from Startup India through AIC-SMUTBI (Atal Incubation Center – Sikkim Manipal University Technology Business Incubation). As more newbie investors enter the investment space, Money Mileage aims to simplify finance, investment, and money management with its innovative platform. The company cherishes a vision to provide best-in-class money management solutions and high-quality financial planning advice to the Indian youth using AI/ML. Furthermore, looking at the youth’s growing dependence on credit cards and BNPL services, Money Mileage envisions promoting the correct way of spending money by educating and creating savings discipline.

Four zealous entrepreneurs co-founded money Mileage – Kashish Chhabra, Mayank Sharma, Anchit Seth, and Abhimanyu Sharma – to offer Indian customers a smart financial assistant. Kashish Chhabra is an MBA in finance and has worked with various US-based companies, managing money through Robo-advisors for US clients. Mayank Sharma has an MBA in Finance/Analytics and has extensive experience in Strategy, Product, and Technology in Top Indian IT firms.

Anchit Seth, on the other hand, is an M.Tech with experience building robust tech architecture for Indian unicorns. And Abhimanyu Sharma is an MBA in Marketing who has worked with top ed-tech startups as a sales and marketing professional. These four are on a mission to help India’s youth with financial planning and investment management, leveraging new-age technologies coupled with AI/ML. As a result, Money Mileage is backed by strong international research and data-driven methodologies to emerge as a one-stop comprehensive financial solution.

At Money Mileage, customers can access SMART Milestones – personally curated baskets that help them achieve financial independence by investing an amount as low as Rs. 200. Using SMART Save, they can also save money efficiently for short-term goals like vehicles, gadgets, or holidays. Money Mileage is also planning to introduce its Robo-Advisor so that investors can RoboFi for their investment and financial planning. Powered by AI, the platform will provide advice across different financial products like Stocks, MF, ETF, Gold, Insurance, etc., to diversify its customers’ investments and help them achieve their financial goals.

Sharing the company’s vision, Kashish Chhabra says, “Over the past few years, India’s investment sector has undergone a significant transformation. An increasing number of youngsters directly invest in investment vehicles like MFs and stocks. In this scenario, Money Mileage seeks to empower budding investors with the right financial assistance at the right time. The platform aims to minimize investment risk and create a financially stable generation of Indian youth through personalised finance and money management solutions. Moreover, it wants to make people aware of the need to build a stable financial future through reliable and informed financial advice.”

Money Mileage is available on both iOS and Android platforms. As investors beyond metros are showcasing interest in making sound financial investments, Money Mileage looks like a fantastic way to maximize your wealth in the best possible way for any future goals.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

About Post Author

RNT Reporter

dhaval.rntoday@gmail.com

https://republicnewstoday.com

The post Money Mileage Ropes in Funding from Startup India through AIC-SMUTBI appeared first on Republic News Today.